# TB-500 Research: Thymosin Beta-4 Mechanism, Studies, and Safety Signals

> The TB-500 and thymosin beta-4 research record: actin sequestration, wound and cardiac findings, the tumor/angiogenesis safety signal, and the fragment-versus-parent distinction, all cited.

Sorted by what the evidence actually establishes — a solved structure and reproduced animal figures up front, the human-data gap and the safety signal labeled plainly.

## Thymosin beta-4: the parent protein behind TB-500

Thymosin beta-4 is a ubiquitous 43-amino-acid peptide and the body's principal G-actin sequestering molecule, near 4963 daltons [1]. TB-500 is its Ac-LKKTETQ fragment — residues 17–23, roughly 889 daltons. This is the single most important framing on the page, so it leads the page: most of the efficacy literature below was generated with the full-length parent, not the fragment, and where that is the case it is stated outright.

The distinction is not pedantry. Full-length thymosin beta-4 carries the complete sequence, can be cleaved at its N-terminus to the separately active peptide Ac-SDKP, and has been the molecule in essentially every wound, cardiac, and clinical study cited here [5]. TB-500 carries only the C-terminal-region actin-binding motif. It is plausible that the motif reproduces some of the parent's actin-related activity, but "plausible" is not "demonstrated," and no completed controlled human trial has tested the heptapeptide for any indication [4]. Read every finding that follows as a thymosin beta-4 finding unless it says otherwise.

## Actin sequestration: the firmest fact in the file

X-ray crystallography of a gelsolin-domain-1–thymosin beta-4 hybrid bound to actin, resolved to 2 ångström, established that thymosin beta-4 forms a one-to-one complex with G-actin and sequesters the monomer by capping both ends, preventing polymerization; the WH2 actin-interacting motif underlies this binding [1]. A solved structure is the strongest kind of evidence in this dataset — it is geometry, not inference.

This matters for TB-500 specifically because the LKKTETQ segment in the fragment is exactly that actin-binding core. The mechanism by which thymosin beta-4 buffers the unpolymerized-actin pool — and thereby influences cell motility and migration — is anchored in a structure, while the downstream physiological claims rest on softer animal and in-vitro work. The hierarchy of confidence on this page tracks that difference.

## Wound healing and re-epithelialization

In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline, increased wound contraction by at least 11% by day seven, and raised collagen deposition and angiogenesis; as little as 10 picograms stimulated keratinocyte migration two- to three-fold [2]. These are large, specific effect sizes — and they are animal and in-vitro figures for the full-length protein, not a human schedule.

The biology is internally consistent. Thymosin beta-4 induces vascular endothelial growth factor (VEGF) in a HIF-1α-dependent manner [11] and promotes matrix metalloproteinase expression during wound repair [13], two mechanistic routes that fit accelerated re-epithelialization and remodeling. A review consolidating this work positions the protein as binding actin, mobilizing cells, decreasing myofibroblast number to reduce scarring, and promoting angiogenesis — the rationale that took thymosin beta-4 into clinical development for dermal and corneal wounds [5].

## Does TB-500 affect the heart?

In mice, thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase, activating the survival kinase Akt; after coronary artery ligation it enhanced early myocyte survival and improved cardiac function [3]. That is a clean positive cardiac result for the full-length protein. The evidence is not one-directional, however: systemic thymosin beta-4 failed to attenuate myocardial ischemia-reperfusion injury in a porcine study, a notable counterpoint [9]. The cardiac picture is genuinely mixed, and it is for the parent protein, not the TB-500 fragment.

## Does TB-500 have neuroprotective effects on the brain?

In a rat embolic middle-cerebral-artery-occlusion model, intraperitoneal thymosin beta-4 at 2 and 12 mg/kg improved neurological function significantly from day 14 through day 56, but 18 mg/kg gave no significant benefit — a non-monotonic dose-response, with a modeled optimal dose near 3.75 mg/kg [7]. Higher was not better. These are animal results for the full-length protein, and human neurological efficacy of the fragment is unproven. An injectable thymosin beta-4 acute-stroke trial was, in fact, withdrawn [10].

## Does TB-500 promote angiogenesis and is that a safety concern?

Thymosin beta-4 induces VEGF in a HIF-1α-dependent manner and promotes endothelial migration [11]. Pro-angiogenic activity is one of the mechanisms that aids tissue repair — and it is also the basis of the oncologic safety signal, because tumors depend on new vessel formation [12]. The same property reads as benefit in a healing wound and as risk in the context of malignancy. This page does not resolve that tension; it reports both halves of it.

## Does TB-500 reduce inflammation?

Full-length thymosin beta-4 reduces myofibroblast number and is associated with suppression of NF-κB and IL-8 signaling in vitro, supporting an anti-inflammatory and anti-fibrotic profile [5]. Reduced myofibroblast number is the mechanistic link to less scarring. Whether the seven-mer reproduces these effects in humans has not been shown in controlled trials [4]; the anti-inflammatory profile is, again, a property documented for the parent protein.

## Thymosin beta-4 as a contemporary exerkine

A 2021 study characterized thymosin beta-4 as a human exerkine and growth factor — a signaling factor released into circulation in response to exercise [15]. That framing is part of why athletic-recovery interest has gathered around TB-500: if the parent protein is a natural exercise-responsive repair signal, the fragment's appeal becomes legible. It does not, however, demonstrate that the administered seven-mer recapitulates an exercise-released full-length protein.

## What does the research say about TB-500 side effects and safety signals?

Rigorous human safety data for the TB-500 fragment are scarce. The most-cited concern is the tumor/angiogenesis signal: thymosin beta-4 is overexpressed in several cancers — pancreatic and colorectal among them — and is implicated in metastasis and tumor angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [12]. This is a recognized safety signal, not a demonstrated human risk for the fragment, and the distinction is the point.

What human safety data exist are for the parent protein. In a Phase 1 study, intravenous synthetic thymosin beta-4 was well tolerated in 40 healthy volunteers up to 1260 mg with only infrequent mild-to-moderate adverse events and no serious adverse events [4]. That characterizes full-length thymosin beta-4 under IV dosing in a controlled setting — it does not characterize the heptapeptide in real-world research use, by other routes, over other durations. Research-grade material quality compounds the uncertainty: peptide identity, purity, and correct sequence are not guaranteed in unregulated supply.

## Is TB-500 safe? What the literature shows

There is no controlled human safety dataset for the TB-500 fragment itself, so "safe" cannot be answered with a fragment-specific trial — that absence is the honest headline [4]. The adjacent evidence is mixed. The parent protein was well tolerated to 1260 mg IV in a Phase 1 study [4]; in dystrophin-deficient mdx mice, chronic thymosin beta-4 increased regenerating muscle fibers but produced no gain in strength, cardiac function, or fibrosis [8]; systemic thymosin beta-4 did not attenuate myocardial ischemia-reperfusion injury in pigs [9]; and the standing tumor/angiogenesis signal is the principal theoretical concern [12]. A clear-eyed reading is confident about the structure and the animal effect sizes, and candid that the fragment's human safety profile is uncharacterized.

## Are there any human clinical trials on TB-500?

No completed controlled clinical trials of the TB-500 fragment exist for any indication [4]. Human data are limited to full-length thymosin beta-4: the Phase 1 IV safety study (well tolerated to 1260 mg) [4] and topical ophthalmic formulations studied in dry-eye and corneal-healing trials. An injectable thymosin beta-4 acute-stroke trial was registered and then withdrawn [10] — a reminder that registered does not mean completed, and that the clinical pipeline for this molecule has partly stalled.

---

A clear-eyed digest of the TB-500 and thymosin beta-4 record, read by glow intensity — the established findings bright, the human-data gaps left dim and labeled, with no clinic behind the aurora and nothing here dispensed.